Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,396,513 shares of the company's stock after acquiring an additional 72,763 shares during the period. Vanguard Group Inc. owned about 10.45% of Moderna worth $1,145,241,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of MRNA. Itau Unibanco Holding S.A. increased its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Moderna in the 1st quarter valued at about $30,000. Vega Investment Solutions purchased a new position in shares of Moderna in the 4th quarter valued at about $45,000. Sentry Investment Management LLC purchased a new position in shares of Moderna in the 1st quarter valued at about $31,000. Finally, Deseret Mutual Benefit Administrators increased its holdings in shares of Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after acquiring an additional 392 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on MRNA shares. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Citigroup began coverage on Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price target on the stock. Barclays dropped their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Monday, August 4th. William Blair restated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Finally, UBS Group dropped their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $43.59.

Moderna Trading Up 4.8%

Shares of MRNA traded up $1.23 during mid-day trading on Wednesday, hitting $26.89. The company's stock had a trading volume of 8,647,828 shares, compared to its average volume of 10,839,467. The firm has a 50-day simple moving average of $29.18 and a 200 day simple moving average of $29.73. The firm has a market capitalization of $10.46 billion, a P/E ratio of -3.57 and a beta of 1.83. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%. Moderna's revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.33) earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.